バイオテクノロジー原料の世界市場-2023年～2030年

市場概要

バイオテクノロジー原料の世界市場は、2022年に566億米ドルに達し、2030年には860億米ドルに達する好成長が予測されています。世界のバイオテクノロジー原料市場は、予測期間中（2023-2030年）に5.5%のCAGRを示すと予測されています。

世界のバイオテクノロジー原料市場は、天然・有機製品に対する需要の高まり、医薬品開発・治療の進歩、パーソナルケア・化粧品への応用拡大、農業バイオテクノロジーの拡大、持続可能性と環境への影響の重視など、さまざまな動向により、近年大きく成長しています。

世界のバイオテクノロジー原料市場は、バイオテクノロジーの進歩、産業全体での採用の増加、パーソナルケアや化粧品への需要の増加、持続可能で自然な製品に対する消費者の需要の高まりなど、複数の要因によって牽引されています。例えば、遺伝子工学、合成生物学、バイオプロセスなどの進歩は、バイオテクノロジー物質の範囲を大幅に広げています。

市場力学

パーソナルケアと化粧品への需要増加が世界のバイオテクノロジー原料市場の成長を促進

パーソナルケアと化粧品の分野では、ナチュラルでオーガニックな製品の需要が高く、そこにバイオテクノロジー原料を使用することが世界のバイオテクノロジー原料市場を牽引します。消費者は、肌や髪に使用する製品への意識が高まっており、一般的な化粧品処方に代わるナチュラル・オーガニック製品を求めています。プロテアーゼやリパーゼといったバイオテクノロジー由来の酵素は、スキンケア製品に適した独自の性質を持っています。

例えば、2022年4月、スウェーデンのバイオテクノロジー企業であるProbi社は、化粧品スキンケア用のユニークなポストバイオティクスの開発のため、世界の原料サプライヤーであるSymrise社と提携しました。この提携の結果、SymFermentが誕生しました。SymFermentは、Symriseブランドのもとで販売されている驚異的なリサイクル成分です。

SymFermentは、ラクトバチルス・プランタラム（Lactiplantibacillus plantarum）菌の発酵プロセスから得られる持続可能な製品別であるラクトバチルス・ファーメント（Lactobacillus Ferment）から作られます。上澄みとしても知られる発酵ブロスは、スキンケア用途に適した優れた特性を持っています。アミノ酸、タンパク質、ミネラル、有機酸など、肌の健康をサポートする微量栄養素を多く含んでいます。

飲食品業界での採用拡大が世界のバイオテクノロジー原料市場の成長を牽引

飲食品業界におけるバイオテクノロジー原料の採用拡大には、食品の品質向上、保存期間の延長、栄養プロファイルの改善など、いくつかの要因があります。消費者は、クリーンラベルで自然な食品をますます求めるようになっており、この分野でバイオテクノロジー成分の需要が高まっています。

例えば、2023年3月、カリフォルニア州を拠点とするバイオテクノロジー新興企業Shiru社は、最初の市場製品であるOleoProを発売しました。この新規製品は、代用肉やその他の植物ベースの料理用途を目的とした植物性タンパク質由来の脂肪です。Shiru社の先駆的なFlourish技術プラットフォームは、持続可能性、高性能、栄養価を兼ね備えた優れた代替脂肪成分であるOleoProを生み出しました。

技術的・製造的課題が市場の成長を妨げている

バイオテクノロジー原料の製造には、特殊なインフラ、設備、経験が必要とされることが多いが、これらは一般には入手不可能であったり、容易に入手できない場合もあります。こうした問題は、製造プロセスの拡張性や費用対効果に影響を及ぼす可能性があります。バイオリアクター、発酵タンク、クリーンルームといった特殊な設備を設置・維持するには、コストと時間がかかります。

バイオテクノロジー・コンポーネントの需要が高まるにつれて、生産手順の拡大がますます重要になってきているが、それは難しいことです。生産数が拡大するにつれて、一貫した製品品質の維持、収率の最適化、再現性の確保が難しくなります。原料、加工条件、生物学的システムのばらつきは、すべて製品の一貫性に影響を与える可能性があり、厳格な品質管理手順が必要となります。したがって、上記の要因のために、予測期間中、市場は低迷すると予想されます。

COVID-19影響分析

COVID-19パンデミックは世界のバイオテクノロジー原料市場に大きな影響を与えました。ワクチンやモノクローナル抗体などのバイオ医薬品に対する需要の高まりは、製剤に使用されるバイオテクノロジー成分の需要を高めました。しかし、サプライチェーンの問題が成分の入手性に影響を与えました。政府や組織はワクチン製造能力の増強に注力し、これが需要を増加させました。

規制の柔軟性と迅速な承認により、バイオテクノロジー物質のタイムリーな入手が容易になっています。パンデミックは研究開発イニシアチブに火をつけ、新たな健康問題に対処するためのバイオテクノロジー要素への継続的な革新と投資の重要性を強調しました。COVID-19が世界のバイオテクノロジー原料市場に与える長期的な影響は、まだ確定していないです。

ロシア・ウクライナ紛争分析

ロシアとウクライナの紛争は、特に影響を受ける国々において、世界のバイオテクノロジー原料のサプライチェーンを混乱させる可能性があります。これにより、世界中でバイオテクノロジー原料の遅延や不足が発生する可能性があります。地政学的な不確実性は、バイオテクノロジー業界における投資決定や企業経営に影響を与え、世界のサプライチェーンを変化させる可能性があります。戦争に関連する規制措置が貿易に影響を及ぼし、コンプライアンスコストが上昇する可能性があります。

さらに、市場の信頼感や投資家心理が損なわれ、バイオテクノロジー分野への資金調達や投資に支障をきたす可能性があります。ロシアとウクライナの地域バイオテクノロジー原料市場は、事業の継続性と国際市場へのアクセスという点で問題に遭遇する可能性があります。紛争が世界のバイオテクノロジー原料市場に与える影響に対応するためには、利害関係者の継続的な監視と柔軟な対応が不可欠です。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • バイオテクノロジー香料への需要の高まり
    • 技術の進歩
  • 抑制要因
    • 原料の入手の困難さ
  • 機会
    • 栄養補助食品への需要の増加
  • 影響分析

第5章 産業分析

• ポーターの5フォース分析
• サプライチェーン分析
• アンメットニーズ
• 規制分析

第6章 COVID-19分析

第7章 ロシア・ウクライナ戦争分析

第8章 タイプ別

• 先行バイオ医薬品原薬
• ジェネリックバイオ原薬/バイオシミラー

第9章 製品別

• モノクローナル抗体
• ワクチン
• サイトカイン
• 融合タンパク質
• 治療用酵素
• ホルモンと成長因子
• 血液因子
• その他

第10章 発現システム別

• 微生物
• 哺乳類
• 植物
• 酵母
• 昆虫
• その他

第11章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • オーストラリア
  • その他アジア太平洋地域
• 中東・アフリカ

第12章 競合情勢

• 競合シナリオ
• 製品ベンチマーク
• 企業シェア分析
• 主な発展と戦略

第13章 企業プロファイル

• Mylan, Inc.
  • 会社概要
  • 製品ポートフォリオと説明
  • 財務概要
  • 主な発展
• Pfizer, Inc.
• Novartis AG
• Sigma-Aldrich（Merck KGaA）
• Bristol-Myers Squibb Company
• Sanofi
• Teva
• AstraZeneca
• BD
• AbbVie Inc.

第14章 付録

Market Overview

The Global Biotech Ingredients Market reached US$ 56.6 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 86.0 billion by 2030. The global biotech ingredients market is expected to exhibit a CAGR of 5.5% during the forecast period (2023-2030).

The global biotech ingredients market has grown significantly in recent years, due to various trends such as rising demand for natural and organic products, advancements in drug development and therapies, growing application in personal care and cosmetics, expansion in agricultural biotechnology, and focus on sustainability and environmental impact.

The global biotech ingredients market is driven by multiple factors such as the advancements in biotechnology, increasing adoption across industries, increasing demand for personal care and cosmetics, and growing consumer demand for sustainable and natural products. For instance, the advancements such as genetic engineering, synthetic biology, and bioprocessing have considerably broadened the scope of biotech substances.

Market Dynamics

The Increasing Demand for Personal Care and Cosmetics is Propelling the Growth of the Global Biotech Ingredients Market

Natural and organic products are in high demand in the personal care and cosmetics sector, use of biotech ingredients in it will drive the global biotech ingredients market. Consumers are becoming more aware of the products they use on their skin and hair, and they are looking for natural and organic alternatives to typical cosmetic formulas. Biotechnology-derived enzymes, such as proteases and lipases, have unique qualities that make them appropriate for skincare products.

For instance, in April 2022, Probi, a Swedish biotech business, collaborated with Symrise, a global ingredient supplier, to develop a unique postbiotic for cosmetic skincare. This partnership resulted in the creation of SymFerment, an extraordinary recycled ingredient marketed under the Symrise brand.

SymFerment is created from Lactobacillus Ferment, a sustainable byproduct obtained from the fermentation process of the bacteria Lactiplantibacillus plantarum. The fermentation broth that results, also known as the supernatant, has exceptional properties that are suitable for skincare applications. It is high in micronutrients that support skin health, such as amino acids, proteins, minerals, and organic acids.

The Growing Adoption in Food and Beverage Industry is Driving the Growth of the Global Biotech ingredients Market

The growing adoption of biotech ingredients in the food and beverage industry is driven by several factors, including the need to enhance food quality, extend shelf life, and improve nutritional profiles. Consumers are increasingly looking for clean-label and natural food items, which has increased demand for biotech components in this area.

For instance, in March 2023, Shiru, a biotech startup based in California, launched its first market offering, OleoPro. This novel product is a plant protein-derived fat intended for substitute meat and other plant-based culinary applications. Shiru's pioneering Flourish technology platform yielded OleoPro, a superior alternative fat ingredient that combines sustainability, high performance, and nutritional value.

The Technical and Manufacturing Challenges is Hampering the Growth of the Market

Biotech ingredient production often requires specialized infrastructure, equipment, and experience that may not be commonly available or easily accessible. These issues can have an impact on the scalability and cost-effectiveness of manufacturing processes. Establishing and maintaining specialized facilities such as bioreactors, fermentation tanks, or cleanrooms can be costly and time-consuming.

Scaling up production procedures is becoming increasingly important as demand for biotech components develops, but it can be difficult. As production numbers expand, maintaining consistent product quality, optimizing yields, and assuring reproducibility become more difficult. Variations in raw materials, processing conditions, and biological systems can all have an impact on product consistency, necessitating stringent quality control procedures. Thus, owing to the above factors, the market is expected to hamper over the forecast period.

COVID-19 Impact Analysis

The COVID-19 pandemic had a huge impact on the global biotech ingredients market. The rising demand for biopharmaceuticals such as vaccines and monoclonal antibodies raised the demand for biotech components used in the formulation. However, supply chain problems impacted ingredient availability. Governments and organizations concentrated on increasing vaccine manufacturing capacity, which increased demand.

Regulatory flexibility and quick approvals facilitated the timely availability of biotech substances. The pandemic sparked research and development initiatives, emphasizing the significance of continual innovation and investment in biotech elements to address new health concerns. The long-term impacts of COVID-19 on the global biotech ingredients market are still being determined.

Russia-Ukraine Conflict Analysis

The Russia-Ukraine conflict has the potential to disrupt global biotech ingredient supply chains, particularly in affected countries. This might cause biotech ingredient delays or shortages around the world. Geopolitical uncertainty may have an impact on investment decisions and company operations in the biotech industry, potentially changing the global supply chain. Regulatory measures relating to the war may have an impact on trade and raise compliance costs.

Moreover, market confidence and investor sentiment may be harmed, thereby hurting funding and investment in the biotech sector. Regional biotech ingredient markets in Russia and Ukraine may encounter problems in terms of business continuity and access to international markets. Continuous monitoring and flexibility are critical for stakeholders navigating the conflict's influence on the global biotech ingredients market.

Segment Analysis

The global biotech ingredients market is segmented based on type, product, expression system, end user, and region.

The Mammalian Expression System Segment is expected to hold a Dominant Position in the Global Biotech Ingredients Market over the Forecast Period.

The mammalian expression system segment is expected to hold 35.9% of market share for the global biotech ingredients market. Owing to the factors such as optimal protein functionality, complex biotech ingredient production, and downstream processing efficiency. Mammalian expression systems, which use mammalian cells, have distinct benefits for producing complex biotech ingredients, particularly therapeutic proteins and antibodies.

Moreover, many collaboration are ongoing for utilization of this mammalian expression system. For instance, in April 2022, Luzhu Biotech and Lonza, a global development and manufacturing partner to the pharmaceutical, biotech, and nutritional industries, have entered into a research and commercial license agreement for Luzhu to use Lonza's GS Xceed Gene Expression System with GS piggyBac transposon technology. Luzhu Biotech is a biopharmaceutical business dedicated to the discovery and development of novel therapeutic candidates for the prevention, control, and treatment of human diseases.

Geographical Analysis

North America Holds a Dominant Position in the Global Biotech Ingredients Market

North America is estimated to hold around 37.8% of the total market share throughout the forecast period, owing to the well-established healthcare infrastructure, favorable reimbursement policies, and presence of leading market players.

The United States is an example of North America's dominance. The country is a center for many biotech ingredient manufacturers as well as prominent research organizations. The headquarters of notable biotech businesses such as Amgen, Genentech, and Biogen are in the United States. These firms have played critical roles in the development and production of biotech ingredients, contributing to the market growth in North America.

Furthermore, renowned research institutions like as Massachusetts Institute of Technology (MIT) and University of California, San Francisco (UCSF) conduct pioneering research, driving innovation and bolstering North America's dominance in the global biotech ingredients market. Therefore, North America dominates the global biotech ingredients market with key companies, research infrastructure, and innovation focus.

Competitive Landscape

The major global players in the market include: Mylan, Inc., Pfizer, Inc., Novartis AG, Sigma-Aldrich (Merck KGaA), Bristol-Myers Squibb Company, Sanofi, Teva, AstraZeneca, BD, and AbbVie Inc., among others.

Why Purchase the Report?

• To visualize the global biotech ingredients market segmentation based on the coating, end user and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of global biotech ingredients market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global biotech ingredients market report would provide approximately 49 tables, 53 figures, and 195 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Type
• 3.2. Snippet by Product
• 3.3. Snippet by Expression System
• 3.4. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Increasing Demand for Biotech Flavors and Fragrance Ingredients
    • 4.1.1.2. Growing Technological Advancements
  • 4.1.2. Restraints
    • 4.1.2.1. Limited Availability of Raw Materials 0wing to the Requirement of Ambient Conditions
  • 4.1.3. Opportunity
    • 4.1.3.1. Increasing Demand for Nutraceuticals
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's 5 Forces Analysis
• 5.2. Supply Chain Analysis
• 5.3. Unmet Needs
• 5.4. Regulatory Analysis

6. COVID-19 Analysis

• 6.1. Analysis of COVID-19
  • 6.1.1. Scenario Before COVID-19
  • 6.1.2. Scenario During COVID-19
  • 6.1.3. Scenario Post COVID-19
• 6.2. Pricing Dynamics Amid COVID-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During the Pandemic
• 6.5. Manufacturers' Strategic Initiatives
• 6.6. Conclusion

7. Russia-Ukraine War Analysis

8. By Type

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 8.1.2. Market Attractiveness Index, By Type
• 8.2. Innovative Biotech APIs*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Generic Biotech APIs/Biosimilar

9. By Product

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 9.1.2. Market Attractiveness Index, By Product
• 9.2. Monoclonal Antibodies*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Vaccines
• 9.4. Cytokines
• 9.5. Fusion Proteins
• 9.6. Therapeutic Enzymes
• 9.7. Hormones and Growth Factors
• 9.8. Blood Factors
• 9.9. Others

10. By Expression System

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Expression System
  • 10.1.2. Market Attractiveness Index, By Expression System
• 10.2. Microbial*
  • 10.2.1. Introduction
  • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 10.3. Mammalian
• 10.4. Plant
• 10.5. Yeast
• 10.6. Insect
• 10.7. Others

11. By Region

• 11.1. Introduction
  • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 11.1.2. Market Attractiveness Index, By Region
• 11.2. North America
  • 11.2.1. Introduction
  • 11.2.2. Key Region-Specific Dynamics
  • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Expression System
  • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.2.6.1. The U.S.
    • 11.2.6.2. Canada
    • 11.2.6.3. Mexico
• 11.3. Europe
  • 11.3.1. Introduction
  • 11.3.2. Key Region-Specific Dynamics
  • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Expression System
  • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.3.6.1. Germany
    • 11.3.6.2. The U.K.
    • 11.3.6.3. France
    • 11.3.6.4. Italy
    • 11.3.6.5. Spain
    • 11.3.6.6. Rest of Europe
• 11.4. South America
  • 11.4.1. Introduction
  • 11.4.2. Key Region-Specific Dynamics
  • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Expression System
  • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.4.6.1. Brazil
    • 11.4.6.2. Argentina
    • 11.4.6.3. Rest of South America
• 11.5. Asia-Pacific
  • 11.5.1. Introduction
  • 11.5.2. Key Region-Specific Dynamics
  • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Expression System
  • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.5.6.1. China
    • 11.5.6.2. India
    • 11.5.6.3. Japan
    • 11.5.6.4. Australia
    • 11.5.6.5. Rest of Asia-Pacific
• 11.6. Middle East and Africa
  • 11.6.1. Introduction
  • 11.6.2. Key Region-Specific Dynamics
  • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Expression System

12. Competitive Landscape

• 12.1. Competitive Scenario
• 12.2. Product Benchmarking
• 12.3. Company Share Analysis
• 12.4. Key Developments and Strategies

13. Company Profiles

• 13.1. Mylan, Inc.*
  • 13.1.1. Company Overview
  • 13.1.2. Product Portfolio and Description
  • 13.1.3. Financial Overview
  • 13.1.4. Key Developments
• 13.2. Pfizer, Inc.
• 13.3. Novartis AG
• 13.4. Sigma-Aldrich (Merck KGaA)
• 13.5. Bristol-Myers Squibb Company
• 13.6. Sanofi
• 13.7. Teva
• 13.8. AstraZeneca
• 13.9. BD
• 13.10. AbbVie Inc.

LIST NOT EXHAUSTIVE

14. Appendix

• 14.1. About Us and Services
• 14.2. Contact Us